Pharmaceuticals

InMed Pharmaceuticals peers beat InMed Pharmaceuticals on 5 of the 8 factors compared.

Fennec Pharmaceuticals Inc () COO Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock in a transaction dated Wednesday, April 17th.

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, August 1st.

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.

Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.

This significant development positions Elite Pharmaceuticals in a favorable position within the generic pharmaceuticals market, offering a cost-effective alternative for patients in need of ADHD medication.

Vanda Pharmaceuticals Inc. VNDA received an acquisition offer from Cycle Pharmaceuticals Ltd worth $8 per share, representing a total cash consideration of $466 million.

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

Given Aerie Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Aerie Pharmaceuticals is more favorable than Crispr Therapeutics.

Given Idera Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Idera Pharmaceuticals is more favorable than Innate Pharma.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.

There could be risk associated with higher competition from Alexion Pharmaceuticals which Achillion Pharmaceuticals (Nasdaq: ) recently.

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) CFO William J. Peters sold 9,800 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, September 16th.

Given Inovio Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than DexCom.